Rubric Capital Management (New York)’s Innate Pharma IPHA Stock Holding History

Rubric Capital Management (New York)’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-250,000	Closed	-$960K	–	71
2020 Q3	$960K	Sell	250,000 -681,673	-73%	-$3.87M	0.09%	61
2020 Q2	$6.38M	Hold	931,673	–	–	0.73%	40
2020 Q1	$6.22M	Sell	931,673 -418,327	-31%	-$2.82M	0.98%	34
2019 Q4	$8.69M	Buy	+1,350,000	New	+$8.3M	0.98%	33

Other funds holding IPHA

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Rubric Capital Management (New York)'s IPHA Position: Q4 2020 in Review

Rubric Capital Management (New York) sold out of Innate Pharma (IPHA) in Q4 2020, closing a stake of 250,000 shares — an estimated $960K sold.

Rubric Capital Management (New York) first reported a position in IPHA in Q4 2019 and held it in 4 quarters. The position peaked at $8.69M in Q4 2019. 4 funds tracked by Wall St. Rank hold IPHA as of Q4 2020.

Rubric Capital Management (New York) reported no remaining Innate Pharma position as of Q4 2020 after selling out during the quarter.
Rubric Capital Management (New York) sold 250,000 Innate Pharma shares in Q4 2020, an estimated $960K.
Rubric Capital Management (New York) first reported a position in Innate Pharma in Q4 2019 and held it in 4 quarters.
Rubric Capital Management (New York)'s Innate Pharma position peaked at $8.69M in Q4 2019.
4 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2020.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2020, filed 16 Feb 2021.